# | Title | Journal | Year | Citations |
---|
1 | An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients | Breast Cancer Research and Treatment | 2010 | 2,480 |
2 | The Nottingham prognostic index in primary breast cancer | Breast Cancer Research and Treatment | 1992 | 913 |
3 | Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis | Breast Cancer Research and Treatment | 2010 | 785 |
4 | Epidemiology of basal-like breast cancer | Breast Cancer Research and Treatment | 2008 | 747 |
5 | A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses | Breast Cancer Research and Treatment | 2008 | 732 |
6 | Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer | Breast Cancer Research and Treatment | 2011 | 687 |
7 | miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients | Breast Cancer Research and Treatment | 2016 | 678 |
8 | Relevance of Breast Cancer Cell Lines as Models for Breast Tumours: An Update | Breast Cancer Research and Treatment | 2004 | 671 |
9 | Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu | Breast Cancer Research and Treatment | 1992 | 670 |
10 | REporting recommendations for tumor MARKer prognostic studies (REMARK) | Breast Cancer Research and Treatment | 2006 | 666 |
11 | Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors | Breast Cancer Research and Treatment | 1995 | 642 |
12 | Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial | Breast Cancer Research and Treatment | 2001 | 629 |
13 | Differentiation of the mammary gland and susceptibility to carcinogenesis | Breast Cancer Research and Treatment | 1982 | 582 |
14 | Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study | Breast Cancer Research and Treatment | 2018 | 564 |
15 | Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study | Breast Cancer Research and Treatment | 2007 | 532 |
16 | Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review | Breast Cancer Research and Treatment | 2012 | 531 |
17 | Role of epidermal growth factor receptor in breast cancer | Breast Cancer Research and Treatment | 2012 | 529 |
18 | The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen | Breast Cancer Research and Treatment | 2007 | 520 |
19 | Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database | Breast Cancer Research and Treatment | 2002 | 479 |
20 | Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer | Breast Cancer Research and Treatment | 2008 | 472 |
21 | Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer | Breast Cancer Research and Treatment | 2014 | 472 |
22 | Pattern of metastatic spread in triple-negative breast cancer | Breast Cancer Research and Treatment | 2009 | 455 |
23 | Breast cancer survivors: Psychosocial concerns and quality of life | Breast Cancer Research and Treatment | 1996 | 450 |
24 | Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry | Breast Cancer Research and Treatment | 2013 | 449 |
25 | Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer | Breast Cancer Research and Treatment | 2011 | 433 |
26 | Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer | Breast Cancer Research and Treatment | 2006 | 432 |
27 | Targeting breast stem cells with the cancer preventive compounds curcumin and piperine | Breast Cancer Research and Treatment | 2010 | 432 |
28 | Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen | Breast Cancer Research and Treatment | 2004 | 418 |
29 | Steroid hormone receptors in breast cancer management | Breast Cancer Research and Treatment | 1998 | 401 |
30 | An overview of prognostic factors for long-term survivors of breast cancer | Breast Cancer Research and Treatment | 2008 | 396 |
31 | The role of vascular endothelial growth factor in pathological angiogenesis | Breast Cancer Research and Treatment | 1995 | 387 |
32 | Depression, quality of life and breast cancer: a review of the literature | Breast Cancer Research and Treatment | 2008 | 375 |
33 | Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro | Breast Cancer Research and Treatment | 2007 | 369 |
34 | Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer | Breast Cancer Research and Treatment | 2002 | 366 |
35 | Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy | Breast Cancer Research and Treatment | 2007 | 349 |
36 | Malignant MCF10CA1 Cell Lines Derived from Premalignant Human Breast Epithelial MCF10AT Cells | Breast Cancer Research and Treatment | 2001 | 346 |
37 | Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research | Breast Cancer Research and Treatment | 1995 | 344 |
38 | Significance of interleukin-6 (IL-6) in breast cancer (review) | Breast Cancer Research and Treatment | 2007 | 342 |
39 | Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer | Breast Cancer Research and Treatment | 1993 | 338 |
40 | Pattern of distribution of cells positive for estrogen receptor α and progesterone receptor in relation to proliferating cells in the mammary gland | Breast Cancer Research and Treatment | 1999 | 338 |
41 | Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression | Breast Cancer Research and Treatment | 1995 | 337 |
42 | Physical activity and risk of breast cancer: a meta-analysis of prospective studies | Breast Cancer Research and Treatment | 2013 | 335 |
43 | Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer | Breast Cancer Research and Treatment | 2017 | 335 |
44 | Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype | Breast Cancer Research and Treatment | 2012 | 333 |
45 | Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA | Breast Cancer Research and Treatment | 2009 | 332 |
46 | Effects of anti-estrogens on bone in castrated and intact female rats | Breast Cancer Research and Treatment | 1987 | 331 |
47 | MDA-MB-435 cells are derived from M14 Melanoma cells––a loss for breast cancer, but a boon for melanoma research | Breast Cancer Research and Treatment | 2007 | 331 |
48 | HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial | Breast Cancer Research and Treatment | 2010 | 330 |
49 | Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue | Breast Cancer Research and Treatment | 2001 | 327 |
50 | An evaluation of the quality of life among long-term survivors of breast cancer | Breast Cancer Research and Treatment | 1996 | 320 |